Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report

Liu,Yan; Zhang,He-Long; Zhang,Ye; Mei,Jia-Zhuan; Lin,Hong-Wei; Guo,Yan‑Wei; Li,Rui-Jun; Meng,Xiang-Rui; Liu,Gui-Ju; Li,Min; Xiao,Peng; Bai,Hua

doi:10.3892/ol.2012.1050

Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report

Authors:
- Yan Liu
- He-Long Zhang
- Ye Zhang
- Jia-Zhuan Mei
- Hong-Wei Lin
- Yan‑Wei Guo
- Rui-Jun Li
- Xiang-Rui Meng
- Gui-Ju Liu
- Min Li
- Peng Xiao
- Hua Bai
View Affiliations

Affiliations: Department of Oncology, Zhengzhou People's Hospital, Southern Medical University, Zhengzhou, Henan 450003, P.R. China, Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Center of Diagnosis and Treatment for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: November 28, 2012 https://doi.org/10.3892/ol.2012.1050
Pages: 699-701

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastrointestinal stromal tumors (GISTs) are rare, and account for 1% of all gastrointestinal neoplasms. GISTs are the most frequent mesenchymal tumors of the gastrointestinal tract. However, the clinical and pathological characteristics of these neoplasms are not adequately understood. The best treatment approach for GISTs remains unclear. In the present study, we report a case of a GIST originating from the stomach. A digestive tract hemorrhage occurred as a complication of sunitinib treatment. This is the first report of a digestive tract hemorrhage due to sunitinib treatment.

View Figures

View References

1.	Hauber AB, Gonzalez JM, Coombs J, et al: Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence. 5:307–314. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Di Scioscio V, Greco L, Pallotti MC, et al: Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors. 3:e172011.
3.	Afuwape OO, Irabor DO and Ladipo JK: Gastrointestinal stromal tumour in Ibadan, Nigeria: a case report and review of current treatment. Afr Health Sci. 11:134–138. 2011.PubMed/NCBI
4.	Issar P, Dwivedi MK, Issar SK, Pal RK and Dewanagan L: Malignant gastrointestinal stromal tumours. Indian J Radiol Imaging. 16:65–67. 2006. View Article : Google Scholar
5.	Wingen CB, Pauwels PA, Debiec-Rychter M, van Gemert WG and Vos MC: Uterine gastrointestinal stromal tumours (GIST). Gynecol Oncol. 97:970–972. 2005. View Article : Google Scholar : PubMed/NCBI
6.	DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 231:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Chen YY, Yeh CN, Cheng CT, et al: Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol. 17:2113–2119. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 152:1259–1269. 1998.
9.	Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
10.	Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastronitestinal stromal tumors. N Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 368:1329–1338. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar
14.	Miettinen M and Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 130:1466–1478. 2006.PubMed/NCBI
15.	Daniels M, Lurkin I, Pauli R, Erbstösser E, et al: Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 312:43–54. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Miettinen M and Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Corless CL, Fletcher JA, Heinrich MC, et al: Biology of gastrointestinal stromal tumors. J Clin Oncol. 22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Bucher P, Villiger P, Egger JF, et al: Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Med Wkly. 134:145–153. 2004.PubMed/NCBI
19.	Annaberdyev S, Gibbons J and Hardacre JM: Dramatic response of a gastrointestinal stromal tumour to neoadjuvant imatinib therapy. World J Surg Oncol. 7:302009. View Article : Google Scholar : PubMed/NCBI
20.	Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 373:1097–104. 2009. View Article : Google Scholar
21.	Ibrahim HH, Ahmad MS, Eskaf WA, et al: Malignant gastrointestinal stromal tumor of the tongue: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 111:e24–e29. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Nowain A, Bhakta H, Pais S, et al: Gastrointestinal stromal tumors: clinical profile, pathogenesis,treatment strategies and prognosis. J Gastroenterol Hepatol. 20:818–824. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Arru JM and Richardson JD: Gastrointestinal stromal tumors: pathogenesis and current treatment. J Ky Med Assoc. 103:211–215. 2005.PubMed/NCBI
24.	Osusky KL, Hallahan DE, Fu A, et al: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. 7:225–233. 2004. View Article : Google Scholar
25.	Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2:471–478. 2003.PubMed/NCBI
26.	Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 9:327–337. 2003.
27.	Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 20:757–766. 2003. View Article : Google Scholar : PubMed/NCBI
28.	O’Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:3597–3605. 2003.PubMed/NCBI
29.	Schueneman AJ, Himmelfarb E, Geng L, et al: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:4009–4016. 2003.PubMed/NCBI
30.	Joensuu H, Trent JC and Reichardt P: Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev Feb. 37:75–88. 2011. View Article : Google Scholar : PubMed/NCBI